Indo US Bio-Tech Ltd (INDOUS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002989,
    "name": "Indo US Bio-Tech",
    "stock_name": "Indo US Bio-Tech",
    "full_name": "Indo US Bio-Tech Ltd",
    "name_url": "stocks-analysis/indo-us-bio-tech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "126.55",
    "chg": 1.55,
    "chgp": "1.24%",
    "dir": 1,
    "prev_price": "125.00",
    "mcapval": "253.76 Cr",
    "mcap": "Micro Cap",
    "scripcode": 541304,
    "symbol": "INDOUS",
    "ind_name": "Other Agricultural Products",
    "ind_code": 61,
    "indexname": "",
    "isin": "INE250Z01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "67.56 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/indo-us-bio-tech-1002989-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Indo US Bio-Tech Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/indo-us-bio-tech-upgraded-from-sell-to-hold-by-marketsmojo-on-27-nov-2025-3743905",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IndoUSBioTech_mojoScore_3743905.png",
        "date": "2025-12-03 11:08:35",
        "description": "Indo US Bio-Tech, a microcap player in the Other Agricultural Products sector, has experienced a revision in its market evaluation metrics, reflecting nuanced shifts across quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of mixed financial performance and subdued stock returns over the past year."
      },
      {
        "title": "Why is Indo US Bio-Tech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-indo-us-bio-tech-fallingrising-3736257",
        "imagepath": "",
        "date": "2025-11-29 01:04:30",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Volatility and Price Movement</strong></p>\n<p>The stock experienced significant intraday fluctuations, with a volatility measure of 6.89%, reflecting a turbulent trading session. It touched an intraday low of ₹135, marking an 8.63% drop from previous levels. The weighted average price indicated that a larger volume of shares was traded closer to this lower price point, suggesting selling pressure dominated the session.</p>\n<p><strong>Trend Reversal After Recent Gains</strong></p>\n<p>After two days of consecutive gains, the stock’s fall on 28 Nov represents a clear trend reversal. This shift indicates that the recent buying momentum has paused, and profit-taking or cautious sentiment may have set in among investors. The underperformance relative to its sector, lagging by 7.35% today,..."
      },
      {
        "title": "How has been the historical performance of Indo US Bio-Tech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-indo-us-bio-tech-3734112",
        "imagepath": "",
        "date": "2025-11-27 22:45:33",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the three-year period ending March 2022, Indo US Bio-Tech's net sales increased from ₹39.76 crores in FY20 to ₹50.06 crores in FY22, reflecting a compound growth trajectory. The total operating income mirrored this trend, with no other operating income reported during these years. Notably, the operating profit before depreciation, interest, and tax (PBDIT) rose from ₹3.98 crores in FY20 to ₹6.95 crores in FY22, indicating enhanced operational efficiency. The operating profit margin improved from 10.01% in FY20 to 13.52% in FY22, underscoring better cost management despite fluctuations in raw material costs and purchase of finished goods.</p>\n<p>Profit before tax (PBT) showed a consistent upward movement, climbing from ₹2.86 crores in FY20..."
      },
      {
        "title": "Indo US Bio-Tech Surges to Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indo-us-bio-tech-surges-20-to-hit-upper-circuit-amid-robust-buying-pressure-3731377",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndoUSBioTech_stocks_hitting_upper_circuit_3731377.png",
        "date": "2025-11-26 12:00:12",
        "description": "Indo US Bio-Tech Ltd witnessed a remarkable trading session on 26 Nov 2025, hitting its upper circuit limit with a near 20% gain. The stock's surge was driven by intense buying interest, resulting in a regulatory freeze on further transactions and highlighting significant unfilled demand in the market."
      },
      {
        "title": "Indo US Bio-Tech Surges with Unprecedented Buying Interest, Hits Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indo-us-bio-tech-surges-to-upper-circuit-amid-unprecedented-buying-interest-3731334",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndoUSBioTech_only_buyers_3731334.png",
        "date": "2025-11-26 11:35:40",
        "description": "Indo US Bio-Tech Ltd witnessed extraordinary buying momentum on 26 Nov 2025, registering a remarkable 19.98% gain in a single trading session. The stock's price action was characterised by an upper circuit scenario with exclusively buy orders in the queue, signalling intense demand and a potential multi-day circuit continuation."
      },
      {
        "title": "Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indo-us-bio-tech-stock-falls-to-52-week-low-of-rs1126-amid-market-underperformance-3728771",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndoUSBioTech_priceRelatedfactors_3728771.png",
        "date": "2025-11-25 10:53:49",
        "description": "Indo US Bio-Tech has reached a new 52-week low of Rs.112.6, marking a significant decline in its stock price amid broader market gains and sectoral advances. The stock's recent performance contrasts sharply with the positive momentum observed in the agricultural sector and the wider market indices."
      },
      {
        "title": "Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indo-us-bio-tech-stock-hits-52-week-low-amidst-continued-downtrend-3728770",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndoUSBioTech_priceRelatedfactors_3728770.png",
        "date": "2025-11-25 10:53:47",
        "description": "Indo US Bio-Tech's stock reached a fresh 52-week low of Rs.112.6 today, marking a significant decline amid broader market gains and sectoral strength. The stock's recent performance contrasts sharply with the overall positive momentum in the agricultural products sector and the wider market indices."
      },
      {
        "title": "Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indo-us-bio-tech-stock-falls-to-52-week-low-of-rs1126-3728769",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndoUSBioTech_priceRelatedfactors_3728769.png",
        "date": "2025-11-25 10:53:46",
        "description": "Indo US Bio-Tech has reached a new 52-week low of Rs.112.6, marking a significant decline amid broader market gains and sectoral strength. The stock’s recent performance contrasts sharply with the positive momentum seen in the agricultural sector and the broader Sensex index."
      },
      {
        "title": "Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indo-us-bio-tech-stock-falls-to-52-week-low-of-rs1126-3728772",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndoUSBioTech_priceRelatedfactors_3728772.png",
        "date": "2025-11-25 10:53:41",
        "description": "Indo US Bio-Tech’s stock price reached a new 52-week low of Rs.112.6 today, marking a significant decline amid broader market gains and sectoral strength. The stock’s recent performance contrasts sharply with the positive momentum seen in the agricultural products sector and the wider market indices."
      }
    ],
    "total": 206,
    "sid": "1002989",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/indo-us-bio-tech-1002989"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "22-Jan-2026",
      "details": "Newspaper Advertisement relating to Unaudited Quarterly Results for the quarter ended on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 21St January 2026 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "21-Jan-2026",
      "details": "Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation 2015 we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday 21st January 2026 at the registered office of the Company situated at 309 Shanti Mall Satadhar Char Rasta Opp. Navrang Tower Sola Road Ahmedabad Gujarat 380061 have considered and approved the following items of business: 1. The Board approved unaudited financial results of the company for the quarter ended 31st December 2025 along with limited review reports obtained from the Auditor of the Company. The Board Meeting commenced at 14.20 P.M. and concluded at 14:40 P.M. You are requested to kindly take the same on record. Thanking you",
      "source": "BSE"
    },
    {
      "caption": "Results- Financial Results For December 31 2025",
      "datetime": "21-Jan-2026",
      "details": "Financial Results",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Indo US Bio-Tech Ltd has declared <strong>2%</strong> dividend, ex-date: 03 Dec 24",
          "dt": "2024-12-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Indo US Bio-Tech Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Aug 23",
          "dt": "2023-08-29",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Indo US Bio-Tech Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-03 11:08:35

Indo US Bio-Tech, a microcap player in the Other Agricultural Products sector, has experienced a revision in its market evaluation metrics, reflecting nuanced shifts across quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of mixed financial performance and subdued stock returns over the past year.

Why is Indo US Bio-Tech falling/rising?

2025-11-29 01:04:30

Intraday Volatility and Price Movement The stock experienced significant intraday fluctuations, with a volatility measure of 6.89%, reflecting a turbulent trading session. It touched an intraday low of ₹135, marking an 8.63% drop from previous levels. The weighted average price indicated that a larger volume of shares was traded closer to this lower price point, suggesting selling pressure dominated the session. Trend Reversal After Recent Gains After two days of consecutive gains, the stock’s fall on 28 Nov represents a clear trend reversal. This shift indicates that the recent buying momentum has paused, and profit-taking or cautious sentiment may have set in among investors. The underperformance relative to its sector, lagging by 7.35% today,...

How has been the historical performance of Indo US Bio-Tech?

2025-11-27 22:45:33

Revenue and Profitability Trends Over the three-year period ending March 2022, Indo US Bio-Tech's net sales increased from ₹39.76 crores in FY20 to ₹50.06 crores in FY22, reflecting a compound growth trajectory. The total operating income mirrored this trend, with no other operating income reported during these years. Notably, the operating profit before depreciation, interest, and tax (PBDIT) rose from ₹3.98 crores in FY20 to ₹6.95 crores in FY22, indicating enhanced operational efficiency. The operating profit margin improved from 10.01% in FY20 to 13.52% in FY22, underscoring better cost management despite fluctuations in raw material costs and purchase of finished goods. Profit before tax (PBT) showed a consistent upward movement, climbing from ₹2.86 crores in FY20...

Indo US Bio-Tech Surges to Upper Circuit Amid Strong Buying Pressure

2025-11-26 12:00:12

Indo US Bio-Tech Ltd witnessed a remarkable trading session on 26 Nov 2025, hitting its upper circuit limit with a near 20% gain. The stock's surge was driven by intense buying interest, resulting in a regulatory freeze on further transactions and highlighting significant unfilled demand in the market.

Indo US Bio-Tech Surges with Unprecedented Buying Interest, Hits Upper Circuit

2025-11-26 11:35:40

Indo US Bio-Tech Ltd witnessed extraordinary buying momentum on 26 Nov 2025, registering a remarkable 19.98% gain in a single trading session. The stock's price action was characterised by an upper circuit scenario with exclusively buy orders in the queue, signalling intense demand and a potential multi-day circuit continuation.

Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance

2025-11-25 10:53:49

Indo US Bio-Tech has reached a new 52-week low of Rs.112.6, marking a significant decline in its stock price amid broader market gains and sectoral advances. The stock's recent performance contrasts sharply with the positive momentum observed in the agricultural sector and the wider market indices.

Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance

2025-11-25 10:53:47

Indo US Bio-Tech's stock reached a fresh 52-week low of Rs.112.6 today, marking a significant decline amid broader market gains and sectoral strength. The stock's recent performance contrasts sharply with the overall positive momentum in the agricultural products sector and the wider market indices.

Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance

2025-11-25 10:53:46

Indo US Bio-Tech has reached a new 52-week low of Rs.112.6, marking a significant decline amid broader market gains and sectoral strength. The stock’s recent performance contrasts sharply with the positive momentum seen in the agricultural sector and the broader Sensex index.

Indo US Bio-Tech Falls to 52-Week Low of Rs.112.6 Amid Market Underperformance

2025-11-25 10:53:41

Indo US Bio-Tech’s stock price reached a new 52-week low of Rs.112.6 today, marking a significant decline amid broader market gains and sectoral strength. The stock’s recent performance contrasts sharply with the positive momentum seen in the agricultural products sector and the wider market indices.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

22-Jan-2026 | Source : BSE

Newspaper Advertisement relating to Unaudited Quarterly Results for the quarter ended on 31st December 2025

Board Meeting Outcome for Outcome Of Board Meeting Held On 21St January 2026 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.

21-Jan-2026 | Source : BSE

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation 2015 we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday 21st January 2026 at the registered office of the Company situated at 309 Shanti Mall Satadhar Char Rasta Opp. Navrang Tower Sola Road Ahmedabad Gujarat 380061 have considered and approved the following items of business: 1. The Board approved unaudited financial results of the company for the quarter ended 31st December 2025 along with limited review reports obtained from the Auditor of the Company. The Board Meeting commenced at 14.20 P.M. and concluded at 14:40 P.M. You are requested to kindly take the same on record. Thanking you

Results- Financial Results For December 31 2025

21-Jan-2026 | Source : BSE

Financial Results

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Indo US Bio-Tech Ltd has declared 2% dividend, ex-date: 03 Dec 24

SPLITS

No Splits history available

BONUS

Indo US Bio-Tech Ltd has announced 1:1 bonus issue, ex-date: 29 Aug 23

RIGHTS

No Rights history available

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."